Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: Exploratory analyses from the TEMPO trial

Annals of the Rheumatic Diseases

Volumn 71, Issue 2, 2012, Pages 206-212

  Curtis, Jeffrey R ^a   Yang, Shuo ^a   Chen, Lang ^a   Park, Grace S ^b   Bitman, Bojena ^b   Wang, Brian ^c   Navarro Millan, Iris ^a   Kavanaugh, Arthur ^d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b AMGEN INC   (United States)

^c KForce Clinical Research   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; METHOTREXATE;

ADULT; ARTICLE; CLASSIFICATION; CONTROLLED STUDY; DECISION TREE; DEMOGRAPHY; DISEASE ACTIVITY; DRUG DOSE ESCALATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TREATMENT RESPONSE; VALIDATION PROCESS;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DECISION TREES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; METHOTREXATE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; RECEPTORS, TUMOR NECROSIS FACTOR; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84855341008     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2011.153551     Document Type: Article

References (23)

1. National Institute for Health and Clinical Excellence . Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis, 2007. http://guidance.nice.org.uk/ TA130/Guidance/pdf/English (accessed 3 March 2011).
2. Ledingham J, Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford) 2005;44:157-63. (Pubitemid 40277395)
3. Furst D E, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 2007;66(Suppl 3):iii2-22.
4. Felson D T, Smolen JS, Wells G, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;63:573-86.
5. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81. (Pubitemid 38296553)
6. http://www.das-score.nl/ (accessed October 1, 2011)
7. Smolen J S, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
8. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005;23 (5 Suppl 39) : S100-8. (Pubitemid 46657517)
9. Breiman L, Spector P. Submodel selection and evaluation in regression: the X-random case. Int Stat Rev 1992;60:291-319.
10. Kohavi R. A study of cross-validation and bootstrap for accuracy estimation and model selection. 14th International Joint Conference on Artificial Intelligence, Montreal, Quebec, Canada, 1995.
11. de Vries-Bouwstra J, Le Cessie S, Allaart C, et al. Using predicted disease outcome to provide differentiated treatment of early rheumatoid arthritis. J Rheumatol 2006;33:1747-53. (Pubitemid 44373205)
12. Smolen JS, Aletaha D. Challenges of predicting treatment response in patients with rheumatoid arthritis. Nat Clin Pract Rheumatol 2005;1:62-3.
13. Verstappen S M, van Albada-Kuipers GA, Bijlsma JW, et al. A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up. Ann Rheum Dis 2005;64:38-43. (Pubitemid 40075272)
14. Gülfe A, Kristensen LE, Geborek P. Six and 12 weeks treatment response predicts continuation of tumor necrosis factor blockade in rheumatoid arthritis: an observational cohort study from southern Sweden. J Rheumatol 2009;36:517-21.
15. Aletaha D, Funovits J, Keystone EC, et al. D isease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 2007;56:3226-35. (Pubitemid 47585417)
16. St Clair E W, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432-43. (Pubitemid 39488667)
17. Lipsky P E, van der Heijde DM, St Clair EW, et al. I nfliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 2000;343:1594-602.
18. Breedveld F C, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37. (Pubitemid 43122183)
19. Bathon J M, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93. (Pubitemid 32162981)
20. Pocock J M, Vasconcelos JC, Ostör AJ. Assessment of anti-TNF-alpha efficacy in rheumatoid arthritis: is 3 months sufficient? Rheumatology (Oxford) 2008;47:1073-6. (Pubitemid 351865937)
21. Kavanaugh A, Klareskog L, van der Heijde D, et al. Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate. Ann Rheum Dis 2008;67:1444-7.
22. Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and regression trees. New York: Chapman & Hall (Wadsworth, Inc.) 1984.
23. van der Heijde D MFM, Schiff M, Keystone EC, et al. Probability to achieve low disease activity at 52 weeks in rheumatoid arthritis (RA) patients treated with certolizumab pegol (CZP) depends on time to and level of initial response. Arthritis Rheum 2009;60:992.